Cresset Asset Management’s Dr. Reddy's Laboratories RDY Stock Holding History

Cresset Asset Management’s Portfolio RDY Stock Details RDY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-49,330	Closed	-$784K	–	2123
2024 Q3	$784K	Buy	49,330 +415	+0.8%	+$6.68K	﹤0.01%	1289
2024 Q2	$745K	Buy	48,915 +4,915	+11%	+$70.4K	﹤0.01%	1234
2024 Q1	$646K	Buy	44,000 +9,430	+27%	+$138K	﹤0.01%	1209
2023 Q4	$481K	Buy	34,570 +6,275	+22%	+$83.9K	﹤0.01%	1255
2023 Q3	$378K	Buy	28,295 +3,615	+15%	+$48.9K	﹤0.01%	1324
2023 Q2	$312K	Buy	+24,680	New	+$288K	﹤0.01%	1506
2021 Q4	–	Sell	-18,785	Closed	-$244K	–	1273
2021 Q3	$244K	Buy	18,785 +265	+1%	+$3.53K	﹤0.01%	944
2021 Q2	$272K	Sell	18,520 -5	-0%	-$70	﹤0.01%	824
2021 Q1	$228K	Buy	18,525 +710	+4%	+$9.12K	﹤0.01%	805
2020 Q4	$254K	Buy	17,815 +2,005	+13%	+$27K	﹤0.01%	615
2020 Q3	$220K	Buy	+15,810	New	+$188K	﹤0.01%	611
2019 Q2	–	Sell	-1,170	Closed	-$9K	–	1403
2019 Q1	$9K	Buy	+1,170	New	+$8.89K	﹤0.01%	1205

Other funds holding RDY

Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

AIM

Aikya Investment Management London, United Kingdom $341M AUM 28.74% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

Cresset Asset Management's RDY Position: Q4 2024 in Review

Cresset Asset Management sold out of Dr. Reddy's Laboratories (RDY) in Q4 2024, closing a stake of 49,330 shares — an estimated $784K sold.

Cresset Asset Management first reported a position in RDY in Q1 2019 and held it in 12 quarters. The position peaked at $784K in Q3 2024. 248 funds tracked by Wall St. Rank hold RDY as of Q4 2024.

Cresset Asset Management reported no remaining Dr. Reddy's Laboratories position as of Q4 2024 after selling out during the quarter.
Cresset Asset Management sold 49,330 Dr. Reddy's Laboratories shares in Q4 2024, an estimated $784K.
Cresset Asset Management first reported a position in Dr. Reddy's Laboratories in Q1 2019 and held it in 12 quarters.
Cresset Asset Management's Dr. Reddy's Laboratories position peaked at $784K in Q3 2024.
248 funds tracked by Wall St. Rank held Dr. Reddy's Laboratories as of Q4 2024.

Based on Cresset Asset Management's 13F filing for Q4 2024, filed 14 Feb 2025.